A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and with Autoimmune Disease)

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

March 13, 2024

Study Completion Date

March 13, 2024

Conditions
Autoimmune Diseases
Interventions
DRUG

VIS171

Participants will receive VIS171 via SC route of administration.

DRUG

Placebo

Participants will receive Placebo via SC route of administration

Trial Locations (10)

1407

Ambulatory for Specialized Medical Help - skin and venereal diseases, Sofia

1612

Comac Medical Ltd, Sofia

1618

MBAL Sveta Sofia, Sofia

1680

Diagnostic and Consultative Center Convex EOOD, Sofia

4002

UMHAT, Plovdiv

6525

Radboud University Medical Center, Gelderland

8011

New Zealand Clinical Research, Christchurch

53127

Universitaetsklinikum Bonn AöR, Bonn

55131

Universitätsmedizin der Johannes-Gutenberg-Universität Mainz, Rheinland-Pfalz

MD 2025

Clinical republican Hospital, Chisinau

All Listed Sponsors
lead

Visterra, Inc.

INDUSTRY